KRN2 bromide
目录号 : GC31748
KRN2是活化T细胞核因子(NFAT5)的选择性抑制剂，其IC50值为0.1μM。
Cas No.:1390654-28-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
KRN2 is a selective inhibitor of nuclear factor of activated T cells (NFAT5), with an IC50 of 0.1 μM.
KRN2 shows much stronger inhibition of NFAT5-dependent reporter activity in RAW 264.7 macrophages than does BBR; the IC50 value is 0.1 μM for KRN2 and 4 μM for BBR. In parallel, 0.5 μM of KRN2 significantly suppresses the LPS-stimulated increase in NFAT5 protein expression in RAW 264.7 macrophages. It is confirmed that LPS-induced NFAT5 mRNA and protein expression is nearly completely blocked by KRN2. Similarly, KRN2 inhibits the translocation of NFAT5 into the nucleus of RAW264.7 cells stimulated with LPS. KRN2 specifically represses LPS-induced NFAT5 promoter activity, whereas it fails to reduce high salt-induced NFAT5 activity in the same cells, which is consistent with the selective inhibition of TLR4-activated NFAT5, but not hypertonicity-induced NFAT5, by KRN2[1].
[1]. Han EJ, et al. Suppression of NFAT5-mediated Inflammation and Chronic Arthritis by Novel κB-binding Inhibitors. EBioMedicine. 2017 Apr;18:261-273.
| Cas No. | 1390654-28-0 | SDF | |
| Canonical SMILES | COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C(CC6=CC=CC=C6F)=C2C=C1.[Br-] | ||
| 分子式 | C27H23BrFNO4 | 分子量 | 524.38 |
| 溶解度 | DMSO : ≥ 60 mg/mL (114.42 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.907 mL | 9.5351 mL | 19.0701 mL |
| 5 mM | 0.3814 mL | 1.907 mL | 3.814 mL |
| 10 mM | 0.1907 mL | 0.9535 mL | 1.907 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。